Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00862433 |
Recruitment Status :
Completed
First Posted : March 16, 2009
Last Update Posted : May 26, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background:
- Vitamin E is an antioxidant that reduces the damaging effects of oxygen in the body. Most American men (90%) and women (96%) do not get enough vitamin E from their diets; however, the amount of vitamin E needed by the body has been studied only in men, not women. In addition, it is unknown whether another antioxidant, vitamin C, helps vitamin E in protecting the body. Because vitamin E is a fat-soluble vitamin, how much body fat a person has could affect the amount of vitamin E needed for protection.
Objectives: This study has three arms to examine vitamin E requirements:
- To determine the amount of fat required to get the best vitamin E absorption from a meal.
- To determine the amount (i.e., best dose) of vitamin E that must be consumed before it can be measured in the blood.
- To examine how vitamin E and vitamin C work together in the body, in conjunction with diet and vitamin supplements.
Eligibility:
- Arms 1 and 2: Women between the ages of 18 and 40 years who have a normal weight and body mass index (BMI) of 27 or less.
- Arm 3: Women between the ages of 18 and 40 years who have a normal weight (BMI 27), who are overweight (BMI > 27), or who are overweight (BMI > 27) and have non insulin-dependent diabetes.
Design:
- Arm 1: Five studies, each lasting 1 month with 1 month off between studies (total study = 10 months). Participants will take 500 1,000 mg of vitamin C twice daily for 2 weeks before admission to the clinical center for 1 week.
- Study 1: Participants will eat breakfast containing a known amount of fat, after which they will take a vitamin E pill as well as receive an IV injection of vitamin E. Other foods contain only negligible amounts of vitamin E. Blood and urine samples will measure levels of vitamin E and other substances.
- Studies 2 5: Outpatient visits will consist of the same tests as in Study 1; however, the amount of fat in the breakfast will range from 0% to 40% in random order. During one of the studies, an adipose tissue biopsy will be collected to determine how much vitamin E is in the tissues.
- Arm 2: Five studies, each lasting 1 month with 1 month off between studies (total study = 10 months). Preparation for Arm 2 is the same as in Arm 1. The proportion of fat, muscle, and water in the body will also be measured.
- Study 1: Participants will eat breakfast containing 30% fat, after which they will take a vitamin E pill as well as receive an IV injection of vitamin E. Conditions and procedures are the same as in Arm 1.
- Studies 2 5: Outpatient visits will consist of the same tests as in Study 1; however, the amount of vitamin E in the breakfast will range from 2 to 30 mg in random order.
- Arm 3: Outpatient (2 to 6 weeks) and inpatient studies (4 to 6 weeks).
- Outpatient study: Participants will take 500 1,000 mg of vitamin C daily and provide blood and urine samples, as well as an adipose tissue sample.
- Inpatient studies: Two vitamin E inpatient studies. Before these begin, participants vitamin C blood levels will be reduced by means of a diet low in vitamin C. Blood tests will determine how quickly vitamin C leaves the body. Once the vitamin C level is reduced, the first vitamin E study will begin.
Study A: The procedure for this study is the same as in Arm 2, Study 1.
Study B: The procedure for this study is the same as in Study A, except that the participants blood vitamin C levels will be higher.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetes Fatty Liver Obesity Healthy Volunteers | Drug: Alpha tocopherol Other: Vitamin E Other: Vitamin C | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 50 participants |
Allocation: | Non-Randomized |
Intervention Model: | Factorial Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women |
Actual Study Start Date : | October 10, 2014 |
Actual Primary Completion Date : | October 21, 2016 |
Actual Study Completion Date : | May 3, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm 1
Determine optimal fat content of meal for optimal absorption of vitamin E
|
Drug: Alpha tocopherol
intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg. Other: Vitamin E Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg. |
Experimental: Arm 2
Determine optimal dose of vitamin E.
|
Drug: Alpha tocopherol
intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg. Other: Vitamin E Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg. |
Experimental: Arm 3
Investigate the relationship between vitamin C status and vitamin E turnover
|
Drug: Alpha tocopherol
intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg. Other: Vitamin E Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg. Other: Vitamin C Oral vitamin C, one gram daily. |
Experimental: NAFLD sub-study
Investigate the relationship between fatty liver disease and vitamin E turnover.
|
Drug: Alpha tocopherol
intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg. Other: Vitamin E Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg. |
- Measure Vitamin E Kinetics [ Time Frame: q min, hrly, daily ]Fractional vitamin E absorption and rates of plasma vitamin E disappearance after a single dose of oral and intravenous vitamin E

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
- INCLUSION CRITERIA:
Subjects to be recruited for the study:
- Healthy women
- Ages 18 to 40 years old
- Able to give informed consent
- Blood pressure <160/90 mm Hg
- Nonobese (BMI less than or equal to 29.9) without diabetes
- Overweight (BMI greater than or equal to 27) without diabetes
-
Overweight (BMI greater than or equal to 27) with mild to moderate non-insulin dependent diabetes (Type 2 diabetes)
- who are treated with diet alone or submaximal doses of oral hypoglycemic agents
- whose fasting blood sugar is < 200mg/dl or HbA1C < 7.5
- with no known target organ damage (End organ damage includes the following: proliferative retinopathy, serum creatinine < 1.8 m/dl, ischemic heart disease, congestive heart failure, peripheral vascular disease and peripheral neuropathy)
- No regular medication other than aspirin (other than oral hypoglycemic agents, hormonal contraceptives and medications taken only on an as-needed basis).
- Willingness to use effective contraceptive methods for the duration of the study
EXCLUSION CRITERIA:
Subjects with the following diseases or abnormalities will not be eligible for the study:
- Digestive abnormalities, such as malabsorption or chronic diarrhea
- Organ malfunction, including (but not limited to) liver disease, pulmonary disease, ischemic heart disease, heart failure, stroke, peripheral vascular disease
- Hypertension (blood pressure >160/90)
- Anemia (hematocrit < 30)
- Current or history of serious or chronic illness, including hyperlipidemia or hypercholesterolemia
- Complications from diabetes such as kidney damage (renal insufficiency, serum creatinine >1.8), eye damage (proliferative retinopathy), diabetic neuropathy, coronary artery disease, or peripheral vascular disease
- Tobacco smoking
- Use of medications (other than oral hypoglycemic agents, hormonal contraceptives and medications taken only on an as-needed basis).
- Alcohol or drug abuse
- Insulin treatment
- Pregnancy or lactation (a urine pregnancy test will be performed on all women with reproductive age before each part of the study or monthly as necessary)
- Positive HIV or hepatitis (b or c) screening tests
- Food allergy, to soy or egg, milk protein (casein), or wheat/gluten
- Known coagulopathy
- Unwillingness to use effective contraceptive methods such as barrier methods for the duration of the study.
Patients on antihypertensive medication are excluded even if blood pressure is well controlled because antihypertensive medication may affect vitamin E status, thus introducing a confounding variable. Whether antihypertensive medication interacts with vitamin E is not
known. Patients on insulin treatment are excluded because Insulin treatment indicates a more severe form of diabetes than the mild to moderate type two diabetes that need only dietary treatment or treatment with submaximal doses of oral hypoglycemic agents for adequate blood sugar control. The effect of insulin administration on vitamin E is unknown, and is a confounding factor that will make data interpretation difficult.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00862433
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | |
Bethesda, Maryland, United States, 20892 |
Principal Investigator: | Mark A Levine, M.D. | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
ClinicalTrials.gov Identifier: | NCT00862433 |
Other Study ID Numbers: |
090097 09-DK-0097 |
First Posted: | March 16, 2009 Key Record Dates |
Last Update Posted: | May 26, 2022 |
Last Verified: | May 3, 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Non-Insulin Dependent Diabetes Antioxidant Lipid Peroxidation Alpha-Tocopherol Non-Alcoholic Fatty Liver Disease |
Health Volunteer HV Normal Weight Overweight Type 2 Diabetes |
Fatty Liver Liver Diseases Digestive System Diseases Vitamins Vitamin E Tocopherols |
alpha-Tocopherol Micronutrients Physiological Effects of Drugs Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents |